The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Levodopa Dose Equivalency in Parkinson's Disease: Updated Systematic Review and Proposals
Open accessAbstract
Background: To compare drug regimens across clinical trials in Parkinson's disease (PD) conversion formulae between antiparkinsonian drugs have been developed. These are reported in relation to levodopa as the benchmark drug in PD pharmacotherapy as ‘levodopa equivalent dose’ (LED). Currently, the LED conversion formulae proposed in 2010 by Tomlinson et al. based on a systematic review are predominantly used. However, new drugs with established and novel mechanisms of action and novel formulations of longstanding drugs have been developed since 2010. Therefore, consensus proposals for updated LED conversion formulae are needed. Objectives: To update LED conversion formulae based on a systematic review. Methods: The MEDLINE, CENTRAL, and Embase databases were searched from January 2010 to July 2021. Additionally, in a standardized process according to the GRADE grid method, consensus proposals were issued for drugs with scarce data on levodopa dose equivalency. Results: The systematic database search yielded 3076 articles of which 682 were eligible for inclusion in the systematic review. Based on these data and the standardized consensus process, we present proposals for LED conversion formulae for a wide range of drugs that are currently available for the pharmacotherapy of PD or are expected to be introduced soon. Conclusions: The LED conversion formulae issued in this Position Paper will serve as a research tool to compare the equivalence of antiparkinsonian medication across PD study cohorts and facilitate research on the clinical efficacy of pharmacological and surgical treatments as well as other non‐pharmacological interventions in PD. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305
Systematic review of levodopa dose equivalency reporting in Parkinson's disease
Tomlinson, C. L., Stowe, R., Patel, S., Rick, C., Gray, R., & Clarke, C. E. (2010) · Movement Disorders · doi:10.1002/mds.23429 · Cited by 4,219
A Randomized Trial of Deep-Brain Stimulation for Parkinson's Disease
Deuschl, G., Schade-Brittinger, C., Krack, P., Volkmann, J., Schäfer, H., Bötzel, K., Daniels, C., Deutschländer, A., Dillmann, U., Eisner, W., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060281 · Cited by 2,944
Self-citationThe role of google scholar in evidence reviews and its applicability to grey literature searching
Haddaway, N. R., Collins, A. M., Coughlin, D., & Kirk, S. (2015) · PLOS ONE · doi:10.1371/journal.pone.0138237 · Cited by 2,387
Grading Strength of Recommendations and Quality of Evidence in Clinical Guidelines
Guyatt, G., Gutterman, D., Baumann, M. H., Addrizzo-Harris, D., Hylek, E. M., Phillips, B., Raskob, G., Lewis, S. Z., & Schünemann, H. (2006) · Chest · doi:10.1378/chest.129.1.174 · Cited by 1,220
Update on treatments for nonmotor symptoms of Parkinson's disease—an evidence‐based medicine review
Seppi, K., Ray Chaudhuri, K., Coelho, M., Fox, S. H., Katzenschlager, R., Perez Lloret, S., Weintraub, D., Sampaio, C., & and the collaborators of the Parkinson's Disease Update on Non‐Motor Symptoms Study Group on behalf of the Movement Disorders Society Evidence‐Based Medicine Committee (2019) · Movement Disorders · doi:10.1002/mds.27602 · Cited by 1,007
Self-citationFox, S. H., Katzenschlager, R., Lim, S., Barton, B., de Bie, R. M. A., Seppi, K., Coelho, M., Sampaio, C., & on behalf of the Movement Disorder Society Evidence‐Based Medicine Committee (2018) · Movement Disorders · doi:10.1002/mds.27372 · Cited by 1,002
Self-citationSubthalamic nucleus or internal pallidal stimulation in young onset Parkinson's disease
Krack, P. (1998) · Brain · doi:10.1093/brain/121.3.451 · Cited by 608
Effect of GPi pallidotomy on motor function in Parkinson's disease
Lozano, A. M., Lang, A. E., Galvez-Jimenez, N., Miyasaki, J., Duff, J., Hutchison, W. D., & Dostrovsky, J. O. (1995) · The Lancet · doi:10.1016/s0140-6736(95)92404-3 · Cited by 603
Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive
Jaeschke, R., Guyatt, G. H., Dellinger, P., Schunemann, H., Levy, M. M., Kunz, R., Norris, S., Bion, J., & for the GRADE working group (2008) · BMJ · doi:10.1136/bmj.a744 · Cited by 577
Hobson, D. E., Lang, A. E., Martin, W. R. W., Razmy, A., Rivest, J., & Fleming, J. (2002) · JAMA · doi:10.1001/jama.287.4.455 · Cited by 553
Levodopa Equivalent Dose Conversion Factors: An Updated Proposal Including Opicapone and Safinamide
Schade, S., Mollenhauer, B., & Trenkwalder, C. (2020) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.12921 · Cited by 338
Self-citationLong-Term Follow-up of Unilateral Pallidotomy in Advanced Parkinson's Disease
Fine, J., Duff, J., Chen, R., Hutchison, W., Lozano, A. M., & Lang, A. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006083422304 · Cited by 266
Anticholinergics for symptomatic management of Parkinson´s disease
Katzenschlager, R., Sampaio, C., Costa, J., & Lees, A. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003735 · Cited by 259
Self-citationUnilateral pallidotomy versus bilateral subthalamic nucleus stimulation in PD: A randomized trial
Esselink, R. A. J., de Bie, R. M. A., de Haan, R. J., Lenders, M. W. P. M., Nijssen, P. C. G., Staal, M. J., Smeding, H. M. M., Schuurman, P. R., Bosch, D. A., & Speelman, J. D. (2004) · Neurology · doi:10.1212/01.wnl.0000103235.12621.c3 · Cited by 254
Zonisamide improves motor function in Parkinson disease: A randomized, double-blind study
Murata, M., Hasegawa, K., Kanazawa, I., & The Japan Zonisamide on PD Study Group (2007) · Neurology · doi:10.1212/01.wnl.0000250236.75053.16 · Cited by 238
Self-citationPringsheim, T., Day, G. S., Smith, D. B., Rae-Grant, A., Licking, N., Armstrong, M. J., de Bie, R. M. A., Roze, E., Miyasaki, J. M., Hauser, R. A., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000012868 · Cited by 205
Self-citationSubthalamic nucleus stimulation in Parkinson's disease
Thobois, S., Mertens, P., Guenot, M., Hermier, M., Mollion, H., Bouvard, M., Chazot, G., Broussolle, E., & Sindou, M. (2002) · Journal of Neurology · doi:10.1007/s004150200059 · Cited by 199
Multilevel Network Meta-Regression for Population-Adjusted Treatment Comparisons
Phillippo, D. M., Dias, S., Ades, A. E., Belger, M., Brnabic, A., Schacht, A., Saure, D., Kadziola, Z., & Welton, N. J. (2020) · Journal of the Royal Statistical Society Series A: Statistics in Society · doi:10.1111/rssa.12579 · Cited by 180
Parkin, S., Gregory, R., Scott, R., Bain, P., Silburn, P., Hall, B., Boyle, R., Joint, C., & Aziz, T. (2002) · Movement Disorders · doi:10.1002/mds.10186 · Cited by 133
Motor and Nonmotor Complications of Levodopa: Phenomenology, Risk Factors, and Imaging Features
Ray Chaudhuri, K., Poewe, W., & Brooks, D. (2018) · Movement Disorders · doi:10.1002/mds.27386 · Cited by 121
Zonisamide improves wearing‐off in Parkinson's disease: A randomized, double‐blind study
Murata, M., Hasegawa, K., Kanazawa, I., Fukasaka, J., Kochi, K., Shimazu, R., & The Japan Zonisamide on PD Study Group (2015) · Movement Disorders · doi:10.1002/mds.26286 · Cited by 121
Self-citationCertain trends in uncertainty and sensitivity analysis: An overview of software tools and techniques
Douglas-Smith, D., Iwanaga, T., Croke, B., & Jakeman, A. J. (2019) · Environmental Modelling & Software · doi:10.1016/j.envsoft.2019.104588 · Cited by 120
Force overflow and levodopa‐induced dyskinesias in Parkinson’s disease
Wenzelburger, R., Zhang, B., Pohle, S., Klebe, S., Lorenz, D., Herzog, J., Wilms, H., Deuschl, G., & Krack, P. (2002) · Brain · doi:10.1093/brain/awf084 · Cited by 102
Self-citationPreclinical and clinical assessment of inhaled levodopa for OFF episodes in Parkinson’s disease
Lipp, M. M., Batycky, R., Moore, J. A., Leinonen, M., & Freed, M. I. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad8858 · Cited by 77
Rocha, J., Falcão, A. C., Santos, A., Pinto, R. M., Lopes, N., Nunes, T., Wright, L. C., Vaz‐da‐Silva, M., & Soares-da-Silva, P. (2014) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-014-1701-2 · Cited by 70
Initial Experience of the Levodopa–Entacapone–Carbidopa Intestinal Gel in Clinical Practice
Öthman, M., Widman, E., Nygren, I., & Nyholm, D. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11040254 · Cited by 67
Binde, C. D., Tvete, I. F., Gåsemyr, J., Natvig, B., & Klemp, M. (2018) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13651 · Cited by 64
Availability of Therapies and Services for Parkinson's Disease in Africa: A Continent‐Wide Survey
Hamid, E., Ayele, B. A., Massi, D. G., Sassi, S. B., Tibar, H., Djonga, E. E., El-Sadig, S., Khedoud, W. A. E., Razafimahefa, J., Kouame-Assouan, A.-É., et al. (2021) · Movement Disorders · doi:10.1002/mds.28669 · Cited by 55
Binde, C. D., Tvete, I. F., Gåsemyr, J., Natvig, B., & Klemp, M. (2020) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-020-02961-6 · Cited by 51
Senek, M., Aquilonius, S., Askmark, H., Bergquist, F., Constantinescu, R., Ericsson, A. B., Lycke, S., Medvedev, A. V., Memedi, M., Ohlsson, F., et al. (2017) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-017-2196-4 · Cited by 48
Rosebraugh, M., Stodtmann, S., Liu, W., & Facheris, M. (2022) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2022.03.012 · Cited by 48
Iso, H. (2011) · The EPMA Journal · doi:10.1007/s13167-011-0067-0 · Cited by 44
Pharmacokinetics, pharmacodynamics, and tolerability of tolcapone
Jorga, K. M. (1998) · Neurology · doi:10.1212/wnl.50.5_suppl_5.s31 · Cited by 39
Song, Z., Zhang, J., Xue, T., Yang, Y., Wu, D., Chen, Z., You, W., & Wang, Z. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.707723 · Cited by 39
Zhuo, C., Zhu, X., Jiang, R.-H., Ji, F., Su, Z., Xue, R., & Zhou, Y.-Y. (2017) · Scientific Reports · doi:10.1038/srep45865 · Cited by 37
Patterns and Determinants of Prescribing for Parkinson's Disease: A Systematic Literature Review
Orayj, K., & Lane, E. (2019) · Parkinson's Disease · doi:10.1155/2019/9237181 · Cited by 36
EQUIDopa: A responsive web application for the levodopa equivalent dose calculator
Verber, D., Novak, D., Borovič, M., Dugonik, J., & Flisar, D. (2020) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2020.105633 · Cited by 34
Agbo, F., Isaacson, S., Gil, R. A., Chiu, Y., Brantley, S. J., Bhargava, P., & NAVIA, B. A. (2021) · Neurology and Therapy · doi:10.1007/s40120-021-00251-6 · Cited by 30
Combination Therapy with Zonisamide and Antiparkinson Drugs for Parkinson’s Disease: A Meta-Analysis
Matsunaga, S., Kishi, T., & Iwata, N. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161068 · Cited by 29
Nausieda, P. A., Hsu, A., Elmer, L. W., Gil, R. A., Spiegel, J., Singer, C., Khanna, S., Rubens, R., Kell, S. H., Modi, N. B., et al. (2015) · Journal of Parkinson s Disease · doi:10.3233/jpd-150622 · Cited by 26
Utilization of anti‐Parkinson drugs in Australia: 1995–2009
Hollingworth, S., Rush, A., Hall, W., & Eadie, M. J. (2011) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2114 · Cited by 25
Yan, R., Cai, H., Cui, Y., Su, D., Cai, G., Lin, F., & Feng, T. (2022) · European Journal of Neurology · doi:10.1111/ene.15651 · Cited by 23
Trends in Antiparkinsonian Medication Use in New Zealand: 1995–2011
Pitcher, T. L., MacAskill, M. R., & Anderson, T. (2014) · Parkinson s Disease · doi:10.1155/2014/379431 · Cited by 18
Safinamide in Clinical Practice: A Spanish Multicenter Cohort Study
Martí‐Andrés, G., Jiménez-Bolaños, R., Arbelo, J. M., Pagonabarraga, J., Durán-Herrera, C., Valenti‐Azcarate, R., & Luquín, M. R. (2019) · Brain Sciences · doi:10.3390/brainsci9100272 · Cited by 18
The Impact in Japan of Regulatory Action on Prescribing of Dopamine Receptor Agonists
Ooba, N., Yamaguchi, T., & Kubota, K. (2011) · Drug Safety · doi:10.2165/11588230-000000000-00000 · Cited by 17
Suzuki, M., Arai, M., Hayashi, A., & Ogino, M. (2020) · eNeurologicalSci · doi:10.1016/j.ensci.2020.100257 · Cited by 17
Network meta-analyses: Methodological prerequisites and clinical usefulness
Christofilos, S. I., Tsikopoulos, K., Tsikopoulos, A., Kitridis, D., Sidiropoulos, K., Stoikos, P., & Kavarthapu, V. (2022) · World Journal of Methodology · doi:10.5662/wjm.v12.i3.92 · Cited by 17
Use of antiparkinson medications among elderly Medicare beneficiaries with Parkinson's disease
Wei, Y. J., Stuart, B., & Zuckerman, I. H. (2010) · The American Journal of Geriatric Pharmacotherapy · doi:10.1016/j.amjopharm.2010.07.002 · Cited by 16
A Causal Inference Approach to Network Meta-Analysis
Schnitzer, M. E., Steele, R. J., Bally, M., & Shrier, I. (2016) · Journal of Causal Inference · doi:10.1515/jci-2016-0014 · Cited by 15
Bianchini, E., Sforza, M., Rinaldi, D., Alborghetti, M., Carolis, L. D., Gatta, F. D., & Pontieri, F. E. (2021) · Neurological Research · doi:10.1080/01616412.2021.1942408 · Cited by 15
Comparison of effectiveness of trihexyphenidyl and levodopa on motor symptoms in Parkinson’s disease
Sahoo, L. K., Holla, V. V., Batra, D., Prasad, S., Bhattacharya, A., Kamble, N. L., Yadav, R., & Pal, P. K. (2020) · Journal of Neural Transmission · doi:10.1007/s00702-020-02257-0 · Cited by 14
Prescribing Pattern for Parkinson’s Disease in Indian Community before Referral to Tertiary Center
Surathi, P., Kamble, N. L., Bhalsing, K. S., Yadav, R., & Pal, P. K. (2017) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/cjn.2017.208 · Cited by 12
Major publications in the critical care pharmacotherapy literature: January–December 2016
Horner, D., Altshuler, D., Droege, C., Feih, J. T., Ferguson, K., Fiorenza, M. A., Greathouse, K. M., Hamilton, L. A., Pfaff, C., Roller, L. K., et al. (2017) · Journal of Critical Care · doi:10.1016/j.jcrc.2017.09.178 · Cited by 11
A Spanish Consensus on the Use of Safinamide for Parkinson’s Disease in Clinical Practice
Pagonabarraga, J., Arbelo, J. M., Grandas, F., Luquín, M. R., Martínez‐Martín, P., Rodríguez-Oroz, M. C., Valldeoriola, F., & Kulisevsky, J. (2020) · Brain Sciences · doi:10.3390/brainsci10030176 · Cited by 10
Swallow, E., Patterson‐Lomba, O., Ayyagari, R., Pelletier, C. L., Mehta, R. K., & Signorovitch, J. (2020) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2020-0042 · Cited by 5
Hatano, T., Kano, O., Sengoku, R., Yoritaka, A., Suzuki, K., Nishikawa, N., Mukai, Y., Nomura, K., Yoshida, N., Seki, M., et al. (2022) · BMC Neurology · doi:10.1186/s12883-022-02600-w · Cited by 5
Ondo, W. G., Coss, P., Christie, M., & Pascual, B. (2018) · Journal of Parkinson s Disease · doi:10.3233/jpd-181427 · Cited by 3
Snineh, M. A., Hajyahya, A., Linetsky, E., Eitan, R., Bergman, H., Israel, Z. H., & Arkadir, D. (2019) · Journal of Parkinson s Disease · doi:10.3233/jpd-191769 · Cited by 3
Metadata
- Authors
- Jost, S. T., Kaldenbach, M., Antonini, A., Martinez‐Martin, P., Timmermann, L., Odin, P., Katzenschlager, R., Borgohain, R., Fasano, A., Stocchi, F., Hattori, N., Kukkle, P. L., Rodríguez‐Violante, M., Falup‐Pecurariu, C., Schade, S., Petry‐Schmelzer, J. N., Metta, V., Weintraub, D., Deuschl, G., Espay, A. J., Tan, E., Bhidayasiri, R., Fung, V. S. C., Cardoso, F., Trenkwalder, C., Jenner, P., Ray Chaudhuri, K., Dafsari, H. S., & the International Parkinson and Movement Disorders Society Non‐Motor Parkinson Disease Study Group
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2023-05-05
- Volume
- 38
- Issue
- 7
- Pages
- 1236-1252
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W4372335396
- Cited by
- 389
- References
- 59
- FWCI
- 18.47
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.